Promedius

Active#35 in South Korea

AI osteoporosis screening

Healthtech›AI osteoporosis screening

Founded2019

HQSeoul

RaisedUSD >25M (KRW >35bn)

Last roundSeries B · Jun 2026

Country of originSouth KoreaListed in the South Korea ranking

Where would you invest?HQ SeoulJurisdiction as cited by the ranking

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
South Korea · all sectors	Top 40	#35	Edition 0 – beta · October 2026	18 Oct 2026

Rank historyOct 2026 · #35First edition: no movements yet.

Estimated valuation

AI · South Korea ranking

≈ USD 79MUSD 63–99M · Tens of M$ High confidence

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Anchor: Last known equity round: Series B · USD 15.4M · Jun 2026
AI adjustment: None

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Funding history

USD >25M (KRW >35bn) raised in total

Date	Round	Amount	Type	Investors	Source
Jun 2026	Series B	USD ~15M (KRW 21.5bn)	Equity	Daewoong Pharmaceutical, Naver	en.sedaily.com

Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Promedius as a PDF, on one of three angles only:

ValuationWhat is Promedius worth?

Versus competitorsIs #35 the right rank?

Who should acquire itStrategic buyers, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.

Invest

Promedius is not open to Backers. A company opens only when a shareholder plans to sell or the company plans to raise.

Back the market instead: your intention joins a pool, passed to the local partner once it reaches critical mass.

Declare an interest in South Korean startups Declare an interest in South Korean healthtech Name Promedius as a preferred company (measures demand, promises nothing)

South Korea poolBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until its pool is passed on. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Promedius?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round. Claiming never changes the rank.

Claim this profile Report an upcoming round →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Press & investor announcements1 source

Read by the AI at the next edition.

Comparable companies in South Korea

Full South Korea ranking →

PFCT#34Fintech › AI credit scoring and online lendingTens of M$wert Intelligence#36Business software › patent intelligenceTens of M$Unastella#33SpaceTech › small launch vehiclesHundreds of M$WireBarley#37Fintech › cross-border remittanceTens of M$

Investors in Promedius: Daewoong Pharmaceutical · Naver

Sources. en.sedaily.com

Last updated: Oct 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.